Adherence to antiretroviral therapy among patients with HIV: A critical link between behavioral and biomedical sciences

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue SUPPL. 3, 2002, Pages

  Ickovics, Jeannette R ^a,b   Meade, Christina S ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Adherence; Antiretroviral therapy; HIV AIDS; Interventions; Review

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; BIOMEDICINE; COMPREHENSION; CONFERENCE PAPER; EVALUATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILLNESS BEHAVIOR; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 0037114882     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200212153-00002     Document Type: Conference Paper

References (36)

1. Yeni P, Hammer S, Carpenter C, et al. Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
2. Paterson D, Swindells S, Mohr J. et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infections. Ann Intern Med 2000;133:21-30.
3. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000;19:124-33.
4. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2001;26:82-92.
5. Weidle P, Ganea C, Irwin K, et al. Adherence to antiretroviral medications in an inner-city population. J Acquir Immune Defic Syndr 1999;22:498-502.
6. Valdez L, Lederman M, Woolley I, et al. Human immunodeficiency virus 1 protease inhibitors in clinical practice: Predictors of virological outcome. Arch Intern Med 1999;159:1771-6.
7. Gifford A, Bormann J, Shively M, Wright B, Richman D, Bozzette S. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386-95.
8. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing, adherence to antiretroviral therapy. AIDS 1999;13:1763-9.
9. Wilson T, Ickovics J, Fernandez M, Koenig L, Walter E. Selfreported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. Am J Obstet Gynecol 2001;184:1235-40.
10. Altice F, Mostashari F, Friedland G. Trust and acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001;28:47-58.
11. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti J-P. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Soc Sci Med 2002;54:1481-96.
12. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-8.
13. Roberts K, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care 2000;12:377-86.
14. Chesney M. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000;30(suppl 2):S171-6.
15. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000;30: S96-116.
16. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence: Results from adult AIDS clinical trials group protocol 370. Antivir Ther 2002; in press.
17. Bartlett J, Demasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple-combination therapy in antiretroviralnaive HIV-1 infected adults. AIDS 2001;15:1369-77.
18. Gallant J, Block D. Adherence to antiretroviral regimens in HIV-infected patients: Results of a survey among physicians and patients. J Int Assoc Physicians AIDS Care 1998;4:32-5.
19. Singh N, Squire C, Sivek M, Wagener M, Hong-Nguyen M, Yu V. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-9.
20. Heszen-Klemens I, Lapinska E. Doctor-patient interaction, patients' health behavior and effects of treatment. Soc Sci Med 1984; 19:9-18.
21. Stone V, Clarke J, Lovell J, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med 1998;13:586-93.
22. Lucas G, Chaisson R, Moore R. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
23. Bangsberg DR, Hecht F. Charlesbois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-3.
24. Weiss L, French P, Waters M, Agins B, Finklestein R. Adherence support: The importance of linkages to clinical care [MoPeB3284]. Paper presented at the XIV International AIDS Conference, Barcelona, 2002.
25. Bamberger J, Unick J, Klein P, Fraser M. Chesney M, Katz M. Helping the urban poor stay with antiretroviral HIV drug therapy: Action point services include counseling, medication, cash incentives, and even e-mail reminders. Am J Public Health 2000;90: 699-701.
26. Haddad M, Gazier R, Urbshott G, Bayoumi A, Rourke S. Patient Support and Education for Promoting Adherence to Highly Active Antiretroviral Therapy for HIV/AIDS (Cochrane Review). Oxford: Update Software; 2001.
27. Knobel H, Carmona A, Lopez J, et al. Adherence to highly active antiretroviral treatment: Impact of individualized assessment. Enferm Infecc Microbiol Clin 1999;17:78-81.
28. Rigsby M, Rosen M, Beauvais J, et al. Cue-dose training with monetary reinforcement: Pilot study of an antiretroviral adherence intervention. J Gen Intern Med 2000;15:841-7.
29. Safren S, Hendriksen E, Boswell S, et al. Twelve-week outcome of a cue-controlled paging system to increase ART adherence [WePeB5864]. Presented at the XIV International AIDS Conference, Barcelona, 2002.
30. Carmona A. Improvement of adherence in severe non-adherent patients after the intervention of a treatment adherence counsellor [WeOrF1365]. Presented at the XIV International AIDS Conference, Barcelona. 2002.
31. Koenig L, Ellerbrock T, Pratt-Palmire M, et al. Prospective predictors of medication adherence: A study of the first six months of highly active antiretroviral therapy (HAART) using electronic monitoring [WePeB58181. Presented at the XIV International AIDS Conference, Barcelona. 2002.
32. Samet JH, Horton N, Dukes K, et al. A randomized controlled trial of a multidimensional intervention to enhance adherence to antiretroviral therapy in HIV-infected patients with a history of alcohol problems [MoPeB3286]. Presented at the XIV International AIDS Conference. Barcelona, 2002.
33. McPherson-Baker S, Malow R, Penedo F, Jones D, Schneiderman N, Klimas N. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care 2000;12: 399-404.
34. Quinn T, Wawer M, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-9.
35. Wainberg M, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977.
36. Little S, Holte S, Routy J, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.